almost always to loss of autonomous walking and forces the patients to use the wheelchair. Lung function becomes increasingly compromised with the duration of the illness and assisted ventilation is required by non-invasive methods or by tracheostomy. Dependence on a wheelchair usually starts a decade after the diagnosis while that on assisted ventilation may start earlier. Respiratory failure is almost always the cause of death in these patients. Today it seems possible to stop this tragic sequence of events by ERT, but for this purpose it is necessary to diagnose the disease at its early stages.

References
1. Van der Beek NA, Hagemans ML, van der Ploeg AT, et al. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg 2006;106:82-6.
2. Müller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007;17:698-706.
3. Van der Ploeg AT, Reuser AJJ. Lysosomal storage disease 2. Pompe disease. Lancet 2008;372:1342-53.
4. American Association of Neuromuscular & Electrodagnostic Medicine Diagnostic criteria for late-onset (childhood and adult) Pompe disease. Muscle Nerve 2009;40:149-60.

S1.4 Cardiovascular involvement in Pompe disease

Giuseppe Limongelli, Fiorella Fratta
Department of Cardiology, Monaldi Hospital, Second University of Naples
E-mail: giuseppe.limongelli@unina2.it

The heart is part of the clinical phenotype of Glycogen storage disease type II (GDS II; Pompe disease; or acid maltase deficiency) since its original description. In 1932, Johannes Pompe, a Dutch pathologist, described the case of a 7-month old infant who died suddenly for a severe idiopathic hypertrophy of the heart (1). Although other cases of massive hypertrophy of the heart have previously been described, Dr. Pompe first demonstrated that not only the heart was involved, but also other organs showed a vacuolar storage of glycogen (“cardiomegala glycogenica”) (1). From a cardiologist’s point of view, Pompe disease is one of the leading cause of familial (idiopathic) hypertrophic cardiomyopathy in neonatal and paediatric age (2). GSD II is broadly divided into two onset forms based on the age symptoms occur.

Infantile onset (“Classic” Form)

In the classic infantile form (Pompe disease), cardiomyopathy and conduction disorders, along with muscular hypotonia (“floppy baby”), macroglossia, and organomegaly, are the cardinal features. Cardiomyopathy is generally of the hypertrophic type, demonstrating a severe thickening of the septum (“asymmetric” hypertrophy), or frequently of both the septum and free walls of the left and right heart (“concentric” hypertrophy). When the septal hypertrophy is very pronounced, a left outflow tract obstruction (favoured by a systolic anterior motion of the anterior mitral leaflet) may be present to worsen the disease (about 30% of the cases). Both diastolic and systolic dysfunction can be observed. Levine JC et al. showed a rapid regression of left ventricular hypertrophy in response to enzyme replacement therapy (ERT) in most of the patients, and systolic ventricular function was preserved despite rapid changes in ventricular mass and size (3).

Glycogen storage involves not only cardiac myocytes, but also the special cells of the conduction system (particularly, the A-V node and the His-bundle cells), representing the hystological background of classical electrocardiographic abnormalities in Pompe disease: pre-excitation patterns (short PR, delta waves), atrio-ventricular blocks and bundle branch abnormalities. The pathogenesis of ventricular pre-excitation (Wolf-Parkinson-White syndrome, WPW, when symtomatic) is unknown, though is clear that the pattern does not reflect the presence of an accessory pathway (as in the classic WPW) (4). The suggested hypothesis are: a) a “direct insulating effect” of the glycogen on the conduction system; b) an “indirect insulating effect” of the glycogen on the conduction system, by the anatomic interruption of the annulus fibrosus (which acts as an “electric insulate” between the atria and the ventricles) (4).

Differential diagnosis

A metabolic or mitochondrial cardiomyopathy may mimic the presentation of GDSII cardiomyopathy (5). The presence of encephalopathy, metabolic acidosis (with or without hypoglycemia), the increase of lactate and lactate/piruvate ratio (normal: < 15:1; abnormal: 25:1) may suggest a mitochondrial cardiomyopathy. Hypoglycemia, with or without variation of plasma ketones, insulin, free fatty acids or carnitine may represent an hallmark of metabolic cardiomyopathies (i.e. beta oxidation deficits).

Infantile onset (“Non Classic” Form)

Compared to the classic form, the onset of the “non classic form” of Pompe disease is generally after the first year of age, with a less severe picture, including muscle weakness, cardiomyopthy, and sometimes macroglossia and organomegaly. Conduction abnormalities and ECG signs of ventricular hypertrophy are generally part of the disease spectrum. Echocardiographic appearance of cardiac hypertrophy is generally less severe and progressive, lacking the left ventricular obstruction and the systolic dysfunction that significantly worsen the classic phenotype. However, the clinical presentation may be extremely various, as demonstrated by Suzuki et al. (6), which reported on a male who developed cardiomyopathy at 12 years of age and died of heart failure at age 15 years without any clinical and/or histological sign of skeletal myopathy.

Differential diagnosis

On the cardiology point of view, the differential diagnosis is with overlapping phenotypes, including syndromic, mitochondrial or metabolic cardiomyopathies (5). Ventricular pre-excitation on the ECG and the presence of idiopathic left ventricular hypertrophy in children are common feature of storage diseases (AMP-kinase disease, Danon disease), and mitochondrial disorders (MELAS, MERFF). Particularly, Danon disease is an X-linked glycogen storage disorder due to the absence of the LAMP-2, lysosome-associated membrane protein 2 (evidenced by Immuno-

Proceedings of the Meeting Course on Type II Glycogenosis: a network for the treatment of Pompe disease
histochemistry or by genetic sequencing). Compared with Pompe disease, cognitive impairment and retinitis pigmentosa may be distinctive features of the diseases.

**Adult Onset**

Adult-onset acid maltase deficiency may simulate limb-girdle dystrophy and the heart may represent a rare finding. Nevertheless, the cardiac phenotype of adults with GDSII is poorly characterized, so far.

Descriptions of heart abnormalities in adults with Pompe disease are sparse. Recently, a relatively large cohort of adults (87 patients, median age 44 years old, 51% males) with Pompe disease have been evaluated (7). A short PR interval was present in 10%, 7% showed a decreased left ventricular systolic function, and 5% had elevated left ventricular mass on echocardiogram. No change in cardiovascular status associated with enzyme replacement therapy (ERT) was observed.

Severe vacuolization of vascular smooth muscle with accumulation of glycogen, particularly involving large and small cerebral arteries with aneurysm formation, have previously been reported (8, 9). Gungor D et al. (10) described survival of 268 patients with Pompe diseases, collected in a prospective international observational study conducted between 2002 and 2009. Out of 34 deaths reported, the cause of death was recognized in 9 patients, including 1 patient who died for aortic dissection. The evidence of smooth muscle involvement seem to be confirmed by the finding of an increased aortic stiffness in adults with Pompe disease (11), which may be due to glycogen storage in the vessel wall, causing reduced vascular elasticity. These findings deserve future investigations.

**SUMMARY CLINICAL SYNOPSIS**

**Principal investigations:**

- ECG: short PR (WPW syndrome), signs of left ventricular hypertrophy with repolarization abnormalities, Ativoventricular and/or intraventricular conduction delays.
- Echo: left ventricular hypertrophy (or, biventricular hypertrophy), with or without: a) left ventricular outflow tract obstruction (about 30%); b) systolic dysfunction; c) diastolic dysfunction (generally, present).

**Other investigations:**

- 24 hours ECG Holter: intermittent WPW and/or conduction delays.
- Functional capacity study: by six minute walking test and/or cardiopulmonary exercise test.
- Cardiac Magnetic Resonance Imaging (CMRI), with late gadolinium analysis: to study cardiac morphology and function, and to determine a non invasive, “texture characterization” of the cardiac muscle.

**References**

1. Pompe JC. Over idiopathische hypertrofie van het hart. Ned Tijdschr Geneeskd 1932;76:304-12.
2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6.
3. Levine JC, Kishnani PS, Chen YT, et al. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 2008;29:1033-42.
4. Arad M, Moskowitz JP, Patel VV, et al. Transgenic mice overexpressing mutant PKRAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003;107:2850-6.
5. Limongelli G, Elliott PM. The genetics of heart failure. Oxford Textbook of Heart Failure 2011. Oxford University Press.
6. Suzuki Y, Tsuji A, Omura K, et al. Km mutant of acid alpha-glucosidase in a case of cardiomyopathy without signs of skeletal muscle involvement. Clin Genet 1988;33:376-85.
7. Forsha D, Li JS, Smith PB, et al for the Late Onset Treatment Study Investigators. Cardiovascular abnormalities in late onset Pompe disease and response to enzyme replacement therapy. Genet Med 2011;13:625-31.
8. Makos MM, McComb RD, Hart MN, et al. Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol 1987;22:629-33.
9. Kretzschmar HA, Wagner H, Hübner G, et al. Aneurysms and vascular degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci 1990;98:169-83.
10. Gängör D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011;16:34.
11. Nemec A, Soliman OL, Geleijnse ML, et al. Increased aortic stiffness in glycogenosis type 2 (Pompe’s disease). Int J Cardiol 2007;120:138-41.

S1.5 Role of the pulmonologist in the late-onset Pompe disease

Giuseppe Fiorentino, Anna Annunziata, Rosa Cauteruccio, Mario Caputi

*Diseases, Pathophysiology and Respiratory Rehabilitation, Monaldi Hospital, Naples, Italy*

E-mail: ambulatoriofiorentino@gmail.com

Pompe disease is a single disease continuum that includes variable neuromuscular symptoms and rates of progression. However, specific clinical features, such as an early onset of respiratory problems preceding limb muscular weakness, distinguish Pompe disease from other neuromuscular diseases in which respiratory insufficiency occurs after loss of ambulation.

The management of Pompe disease also differs from other neuromuscular diseases in that specific treatment is now available, making early recognition of the disease a priority. Late-onset form of Pompe disease, that may occur at any age after the first year of life, is characterized by slow and progressive loss of function of skeletal muscles. Respiratory failure is the major cause of morbidity and mortality. The evaluation and monitoring of parameters such as FVC, MIP, MEP, blood gases, together with the clinical examination can delineate the profile and the decline in lung function, in order to provide early and effective therapeutic intervention. In patients with restrictive chest wall disease, the indication in VMD should be in the presence of symptoms such as fatigue, dyspnea, morning headaches, disturbed sleep, daytime hypersomnia associ-